Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J consumer sales

This article was originally published in The Tan Sheet

Executive Summary

Fourth quarter sales for McNeil Consumer & Specialty Pharmaceuticals rose 6% to $423 mil. in the U.S. but declined 8% in international markets to $67 mil. For the year, McNeil's domestic revenues increased 6% to $1.54 bil. and international sales dropped 10%, resulting in worldwide sales of $1.8 bil. for 2002, up 3%. Johnson & Johnson highlights strong growth for McNeil Nutritionals' Splenda sweetener and Viactiv calcium chews during the year in a 1Jan. 21 financials release. J&J women's health products recorded 2% worldwide sales gain to $1.25 bil. for the year while skin care revenues advanced 13% to $1.57 bil. on continued strength of Neutrogena, Clean & Clear, Aveeno...

You may also be interested in...



Viactiv

Flavored soft calcium chews in new resealable "to-go" packs will reach retail shelves nationwide in May in time for National Osteoporosis Awareness and Women's Health Months, McNeil Nutritionals announces Feb. 19. Ten-chew packs will carry a suggested retail price of $1.99 and will be available in the original milk chocolate flavor as well strawberry cream - a new flavor that debuted in September. The launch follows strong growth for the brand in 2003 (1"The Tan Sheet" Jan. 27, 2003, In Brief)...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel